{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.99","value":"2.73"},{"groupId":"OG001","spread":"1.72","value":"2.32"},{"groupId":"OG002","spread":"0.944","value":"1.95"},{"groupId":"OG003","spread":"1.18","value":"2.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"43"}],"units":"Participants"}],"description":"Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.","dispersionType":"Standard Deviation","groups":[{"description":"PCI-32765 420 mg per day\n\nPCI-32765","id":"OG000","title":"Cohort 1"},{"description":"PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"OG001","title":"Cohort 2"},{"description":"PCI-32765 840 mg per day\n\nPCI-32765","id":"OG002","title":"Cohort 3"},{"description":"PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"OG003","title":"Cohort 4"}],"paramType":"MEAN","populationDescription":"All subjects who received at least one dose of study treatment and had evaluable pharmacokinetic data.","reportingStatus":"POSTED","timeFrame":"Procedure was performed up to 60 weeks.","title":"Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).","type":"SECONDARY","unitOfMeasure":"hours"}